51st week of 2014 patent applcation highlights part 39 |
Patent application number | Title | Published |
20140370040 | METHODS FOR IDENTIFYING TUMOR-SPECIFIC POLYPEPTIDES - The present invention provides methods for identifying tumor-specific polypeptides, polypeptides so identified, and methods for their use. | 2014-12-18 |
20140370041 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA - The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin. | 2014-12-18 |
20140370042 | Stabilized Antiviral Fusion Helices - Internally cross-linked peptides useful for interfering with Respiratory Syncytial Virus (RSV) infection is based on RSV-F protein. These peptides are capable of reducing infection in cellular and animal models. | 2014-12-18 |
20140370043 | VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINE - The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position ( | 2014-12-18 |
20140370044 | MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSES - The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells. | 2014-12-18 |
20140370045 | USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions. | 2014-12-18 |
20140370046 | BETA-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS - Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell. | 2014-12-18 |
20140370047 | PRODUCTS AND METHODS - The invention relates to fungal cells and spores, as well as extracts of either, for use, in particular, in prevention or treatment of | 2014-12-18 |
20140370048 | COMPOSITION FOR TREATMENT OR PREVENTION OF HYPERLIPIDEMIA, CONTAINING ALCOHOL EXTRACTS OF OLIGOPORUS TEPHROLEUCUS - The present invention relates to a composition for the treatment or prevention of hyperlipidemia, the composition containing alcohol extracts of | 2014-12-18 |
20140370049 | METHOD FOR FORMULATING A VACCINE CONTAINING AT LEAST TWO ANTIGENS CAPABLE OF ADSORBING ONTO ALUMINIUM OXYHYDROXIDE - The subject matter of the invention is a method for preparing a vaccine composition comprising at least aluminium oxyhydroxide (AlOOH), and at least the hepatitis B surface antigen and the | 2014-12-18 |
20140370050 | PIV5 AS ONCOLYTIC AGENT - The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VAC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI−), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI−, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-5157A, rPIV5-P-5308A, A1981D, rPIV5-F-5443P, rPIV5-MDA7, rPIV5ASH-CPI−, or rPIV5ASH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents. | 2014-12-18 |
20140370051 | CHIMERIC NON-INTEGRATING LENTIVIRAL GENOMES AS VACCINES AGAINST HIV-1 - Novel nucleic acids include non-integrative chimeric retroviral genomes including the 5′ and 3′ long terminal repeat sequences (LTRs) of the caprine lentivirus: the Caprine Arthritis Encephalitis Virus (CAEV) or of another retrovirus not integrating human cells and at least one viral gene of another retrovirus. A vector including such a nucleic acid, an immunogenic or vaccinal composition including the vector or the nucleic acid, as well as their use for treating and/or preventing an infection by a retrovirus or a disease induced by a pathogenic agent are also described. | 2014-12-18 |
20140370052 | INHIBITORS OF SIALOADHESIN FOR THE TREATMENT OF DISEASES CAUSED BY ENVELOPED VIRUSES - The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin. | 2014-12-18 |
20140370053 | ADJUVANT-SPARING MULTI-DOSE INFLUENZA VACCINATION REGIMEN - An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant. | 2014-12-18 |
20140370054 | METHODS FOR INHIBITION OF TYPE 1 DIABETES - This disclosure is directed to methods of inhibiting the development of type 1 diabetes in a subject, including methods of preventing development of type 1 diabetes. The disclosed methods involve pre-partum vaccination of future mothers against rotavirus. Methods of decreasing the prevalence of type 1 diabetes are also disclosed. | 2014-12-18 |
20140370055 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides. | 2014-12-18 |
20140370056 | Mucosal Vaccine Using Cationic Nanogel - A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route. | 2014-12-18 |
20140370057 | ATTENUATED LIVE BACTERIA WITH INCREASED ACID RESISTANCE AND METHODS OF USE THEREOF - The present invention relates to inducing acid resistance in a bacterium and methods of increasing the acid resistance of an acid sensitive bacterium. | 2014-12-18 |
20140370058 | ONE DOSE VACCINATION AGAINST MYCOPLASMA INFECTIONS OF PIGS - The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by | 2014-12-18 |
20140370059 | USE OF mTOR INHIBITORS TO ENHANCE T CELL IMMUNE RESPONSES - It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog. | 2014-12-18 |
20140370060 | Tear Film Stability - The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue. | 2014-12-18 |
20140370061 | COMBINATION OF ACTIVE INGREDIENTS FOR COSMETIC PREPARATIONS - A combination of active substances for cosmetic preparations contains hyaluronic acid and at least one of its derivatives. At least 10 percent by weight is used in long-chain form with a molecular weight of at least 1,000,000 daltons. At least 2 percent by weight is used in short-chain form with a molecular weight not more than 200,000 daltons. | 2014-12-18 |
20140370062 | COMPOSITION WITH A CONTINUOUS OIL PHASE CONTAINING AT LEAST ONE LIPOPHILIC ORGANIC UV-SCREENING AGENT AND HYDROPHOBIC SILICA AEROGEL PARTICLES - The present invention relates to a composition comprising, in a cosmetically acceptable medium, at least one continuous oil phase, characterized in that the oil phase comprises a) at least one non-volatile non-cyclic silicone oil with a viscosity at 25° C. ranging from 4 to 5000 mm | 2014-12-18 |
20140370063 | COSMETIC COMPOSITION COMPRISING SILICA AEROGEL PARTICLES AND AN EMULSIFYING SILICONE ELASTOMER - A subject matter of the present invention is a composition for topical application comprising hydrophobic silica aerogel particles and at least one emulsifying silicone elastomer. Another subject matter of the invention is a method for the cosmetic treatment of keratinous substances which consists in applying, to the keratinous substances, a composition as defined above, and also the use of this composition in the cosmetic or dermatological field and in particular for caring for, protecting and/or making up the skin of the body or face or for caring for the hair. The composition of the invention makes it possible to improve the sensory properties of cosmetic compositions provided in the anhydrous or emulsified form by making possible more complete absorption, without a greasy or unpleasant residual film on the skin. | 2014-12-18 |
20140370064 | FILM-FORMING COMPOSITIONS OF SELF-CROSSLINKABLE NANOGEL STAR POLYMERS - A film-forming composition comprises a solvent and unimolecular nanoparticles of a self-crosslinkable nanogel star polymer. The nanogel star polymer comprises i) a crosslinked polymer core (nanogel core) and ii) 6 or more independent polymer arms covalently linked to the core by respective first end groups. A plurality of the arms comprise reactive groups for effecting crosslinking of the nanoparticles. An essentially solvent-free film layer comprising the nanoparticles self-crosslinks, optionally assisted by subjecting the film layer to a thermal treatment and/or a photochemical treatment. A surface treated article comprising the crosslinked film layer can effectively inhibit growth of and/or kill Gram-negative microbes, Gram-positive microbes, fungi, and/or yeasts. | 2014-12-18 |
20140370065 | ANHYDROUS SUSPENSIONS AND ANTIMICROBIAL GELS COMPRISING BIOACTIVE GLASSES AND APPLICATIONS THEREOF - An anhydrous suspension including a) particles of bioactive glass having a mean particle size less than or equal to 20 μm; and an ester and/or amide with a molecular weight less than or equal to 100,000, and/or an alcohol. A gel obtainable by contacting the anhydrous suspension with water is also disclosed. Applications of the suspension and gel are also disclosed. | 2014-12-18 |
20140370066 | Antimicrobial Glass-Ceramics - The application discloses the formation of antimicrobial glass-ceramic articles having an amorphous phase and a crystalline phase and an antimicrobial agent selected from the group consisting of silver, copper and a mixture of silver and copper. The antimicrobial glass-ceramic can have a Log Reduction of >2. | 2014-12-18 |
20140370067 | Method and applicator for the perioperative disinfection of medical instruments to be inserted through non-natural openings - The invention relates to means and methods for the disinfection of an insertion channel to prevent in particular catheter sepsis, which significantly reduces the carry-over of germs even out of deeper skin layers by means of medical instruments, such as catheters, to be introduced into non-natural openings and also permits the decontamination of perioperatively contaminated medical instruments. The disinfection of the insertion channel is achieved by means of a method for the perioperative coating of a medical instrument to be inserted into an invasively produced bodily opening before use, comprising the application of a preferably viscous or foam-like composition containing at least one anti-infective compound, preferably a gel having octenidine, by means of an applicator, such that when said gel is used, the composition is also specifically effective in the first millimeters of the insertion channel. Furthermore, an immediate disinfecting action is provided over the entire coated surface. | 2014-12-18 |
20140370068 | PLACENTAL TISSUE GRAFTS - A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion. | 2014-12-18 |
20140370069 | METHODS FOR TREATING AN ESTABLISHED MYOCARDIAL INFARCTION - Methods for treating an established myocardial infarction, including treatment with an epicardial construct containing stromal vascular fraction (SVF) from adipose tissue which may be seeded onto a biocompatible substrate, which preserves microvascular function and LV contractile mechanisms. | 2014-12-18 |
20140370070 | Methods for Producing Hair Microfollicles and De Novo Papillae and Their Use for In Vitro Tests and In Vivo Implantations - The present invention relates to a method for producing hair microfollicles comprising the steps of: a) providing de novo papillae, b) providing other cell populations selected from the group of fibroblasts, keratinocytes and melanocytes, and co-culturing the de novo papillae with at least one other cell population in non-adherent culture vessels. The present invention relates also to methods of producing de novo papillae usable in said method for producing hair microfollicles. | 2014-12-18 |
20140370071 | Medical Devices Comprising Polymeric Drug Delivery Systems With Drug Solubility Gradients - Disclosed are drug delivery systems comprising drugs admixed with polymers having drug solubility gradients and methods of making the polymers. Also disclosed are medical devices having coatings thereon comprising the drug solubility gradient-containing polymers and at least one drug. | 2014-12-18 |
20140370072 | PROHEALING PIEZOELECTRIC COATINGS - Provided herein is a prohealing piezoelectric coating and the method of making and using the same. | 2014-12-18 |
20140370073 | BIOLOGICALLY DEGRADABLE COMPOSITIONS FOR MEDICAL APPLICATIONS - A medical article is disclosed, comprising a biologically degradable AB block copolymer and a biologically degradable polymer that is capable, at equilibrium and at room temperature, of absorbing less than about 5 mass % water. | 2014-12-18 |
20140370074 | ADHERING COMPOSITION AND METHODS OF APPLYING THE SAME - A method of in-situ adhering comprising providing pre-gel that comprises a mixture of at least one phenol-based compound and at least one water miscible polymer selected from at least one of a naturally existing form of a carbohydrate, a synthetically prepared form of carbohydrate and a salt of an anionic polysaccharide; spreading a layer of the pre-gel onto a first surface; adding a solid support, comprising at least one cross linking agent capable of interacting with the water miscible polymer to the pre-gel; and allowing the pre-gel to cure and adhere onto the first surface. | 2014-12-18 |
20140370075 | REINFORCED, LAMINATED, IMPREGNATED, AND COMPOSITE-LIKE MATERIALS AS CROSSLINKED POLYVINYL ALCOHOL HYDROGEL STRUCTURES - Reinforced, laminated, impregnated, and materials with composite properties as cross linked polyvinyl alcohol hydrogel structures in bulk or cellular matrix forms that can take essentially any physical shape, or can have essentially any size, degree of porosity and surface texture. They have a wide range of physical properties, unusual and unique combinations of physical properties and unique responses to stress fields, which allows for their use in many end use applications. | 2014-12-18 |
20140370076 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL - The present invention provides a transdermal drug delivery system comprising donepezil or its pharmaceutically acceptable salt and method of making the same. | 2014-12-18 |
20140370077 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING FENTANYL - The present invention provides a transdermal drug delivery system comprising fentanyl or its pharmaceutically acceptable salt and method of making the same. | 2014-12-18 |
20140370078 | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds - Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. | 2014-12-18 |
20140370079 | METHOD FOR TARGETING VASCULAR RHOJ FOR INHIBITING TUMOR ANGIOGENESIS - The present application describes a method of inhibiting tumor growth including contacting the tumor with a compound that inhibits activity of RhoJ protein. | 2014-12-18 |
20140370080 | HISTONE DEACETYLASE (HDAC) INHIBITORS FOR TREATMENT OF POST-SURGICAL ADHESIONS - The present invention relates generally to methods, compounds and compositions for treatment of adhesions, such as surgical adhesions. | 2014-12-18 |
20140370081 | STABLE CRYSTAL MODIFICATIONS OF DOTAP CHLORIDE - The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R,S)-, (25)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments. | 2014-12-18 |
20140370082 | CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS - The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA | 2014-12-18 |
20140370083 | 5-AMINOSALICYLIC ACID CAPSULE FORMULATION - A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed. | 2014-12-18 |
20140370084 | ESTRADIOL FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2014-12-18 |
20140370085 | Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same - An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed. | 2014-12-18 |
20140370086 | SUBLINGUAL IMMUNOTHERAPY WITH REDUCED ORAL ITCHINESS - Sublingual immunotherapy (SLIT) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with SLIT, which can improve patient compliance. An antihistamine and/or a leukotriene inhibitor can also be added along with the mast cell stabilizer. Multi-layer and/or coated tablets, and flexible paired ampoules with special features to advantageously time the dose of the allergen relative to the dose of the mast cell stabilizer, have been provided to effectively administer the improved sublingual immunotherapy in a highly convenient manner. Methods, preparations, and apparatuses for administration of SLIT, apparatus for sequentially dispensing, methods for producing a sequence of allergen doses with reduced adverse reactions, methods for producing a stock solution for dilution, and methods for producing cooperative pre-filled vials are also disclosed. | 2014-12-18 |
20140370087 | NOVEL USE OF ANGIOGENIN - The present invention provides a pharmaceutical composition for the prevention or treatment of glaucoma, wherein the pharmaceutical composition includes angiogenin or a fragment thereof as an active ingredient. Angiogenin or a fragment thereof according to the present invention activates aqueous humor outflow due to NO generation increase, Schlemm's canal expansion, and intercellular interval widening, thereby reducing intraocular pressure. Accordingly, angiogenin and a fragment may be useful for the prevention and treatment of glaucoma. | 2014-12-18 |
20140370088 | COMPOSITIONS AND METHODS FOR DELIVERY OF OMEPRAZOLE PLUS ACETYLSALICYLIC ACID - The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof. | 2014-12-18 |
20140370089 | DIETHYL-[6-(4-HYDROXYCARBAMOYL-PHENYL-CARBAMOYLOXY-METHYL)-NAPHTHALEN-2-YL- -METHYL]-AMMONIUM CHLORIDE FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY - The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. | 2014-12-18 |
20140370090 | IN SITU, LIQUID-ACTIVATED FILM COATED TABLETS AND A PROCESS FOR MAKING THE SAME - Tablets and other objects are film coated by including in the tablet a film-forming polymer that is activated upon contact with an activating amount of liquid. The film-forming polymer, e.g., a cellulosic ether, is homogeneously mixed with the other ingredients of the tablet, shaped into any desirable form, loaded into a conventional coating apparatus, and sprayed or foamed with an activating amount of fluid, e.g., water, alcohol, etc., and dried. This coating process eliminates potential problems such as spray nozzle clogging, inappropriate coating fluid viscosity, and the inability to properly atomize the coating fluid. This coating process does not impart any appreciable weight or thickness gain to the tablet. | 2014-12-18 |
20140370091 | Method for Producing Aqueous Enteric Coating Liquid, Solid Preparation, and Method for Producing Same - An enteric preparation having a film-forming property and acid resistance is provided by using a simple and efficient method without using a special cooling apparatus. More specifically, provided is a method for producing an aqueous enteric coating liquid including the steps of: partially neutralizing an aqueous suspension including a cellulosic enteric material with an aqueous alkali solution, and mixing the partially-neutralized aqueous suspension with a plasticizer. Also provided is a solid preparation including a core including a drug and a coating portion obtained by coating the core with the produced aqueous enteric coating liquid. Further, provided is a method for producing a solid preparation, including respective steps in the method for producing an aqueous enteric coating liquid and a step of coating a core including a drug with the produced aqueous enteric coating liquid. | 2014-12-18 |
20140370092 | FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-α production in mammals. | 2014-12-18 |
20140370093 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 2014-12-18 |
20140370094 | SILK-BASED SCAFFOLD PLATFORM FOR ENGINEERING TISSUE CONSTRUCTS - The inventions provided herein relate to silk-based scaffolds and methods of producing the same, which can be used for a range of tissue engineering applications. The fabrication methods described herein provide a versatile platform to incorporate hollow conduits (e.g., for nutrient/oxygen delivery) through three-dimensional silk-based scaffolds that have tunable bulk properties (e.g., but not limited to, porosity, mechanical, degradation rate) and allow endothelialization and/or cell compartmentalization, for engineering a variety of complex tissue equivalents. | 2014-12-18 |
20140370095 | Weight Loss Compositions and Methods for Appetite Suppression - A beverage composition for weight loss is provided which includes cayenne pepper; a palate enhancing agent selected from the group consisting of fruits, herbs, vegetables and mixtures thereof, the agent including pulp of the fruits, the herbs, the vegetables or the mixtures thereof; a least two spices selected from the group consisting of black or white pepper, ginger, cinnamon, mustard seed and mixtures thereof; and water in an amount from 80 to 99% by weight of the composition; and wherein the composition has a total calorie content from 0 to 100 based on 100 gram of the composition. | 2014-12-18 |
20140370096 | GAS TRANSPORTING RHEOLOGICAL MEDIUM, END USES AND RELATED APPARATUS-METHOD - A two-phase mixture is provided having a dissolved gas and a suspension of bubbles in a liquid. Methods for making, maintaining, and using the two-phase mixture are also provided. The gas molecules may be introduced into the liquid at a high velocity under elevated pressure to form a supersaturated solution that retains the dissolved gas concentration in solution when the solution is exposed to ambient conditions. The mixture may be used in a number of applications where high concentrations of gas must be retained in solution during prolonged exposure to ambient conditions. An example is the treatment of wounds to non-surgically remove dead, devitalized, contaminated and foreign matter from tissue cells. | 2014-12-18 |
20140370097 | STERILE PHARMACEUTICAL COMPOSITIONS - The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects. | 2014-12-18 |
20140370098 | TINTED EMULSION - The present invention relates to a cosmetic composition for caring for and/or making up keratin materials which is in the form of an oil-in-water emulsion which undergoes phase inversion when it is applied to said keratin materials, comprising: (i) at least one pigment having a particle size greater than 100 nanometers, and (ii) a combination of at least one hydrophilic surfactant and at least one lipophilic surfactant. It also relates to the associated cosmetic process. | 2014-12-18 |
20140370099 | ARTIFICIAL ANTIGEN PRESENTING CELLS HAVING A DEFINED AND DYNAMIC SHAPE - Compositions and methods comprising asymmetrical artificial antigen presenting cells (aAPCs) are disclosed. The non-spherical aAPCs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy. | 2014-12-18 |
20140370100 | BONE FILLER COMPOSITION - A bone filler composition comprises a mixture of a curable calcium phosphate based bone filler which is formed from a liquid component and a calcium phosphate based powder component, and a formulation which comprises a bisphosphonate in particulate form. The particles of the bisphosphonate being embedded in particles of a polymeric material which resorbs when the formulation is implanted. | 2014-12-18 |
20140370101 | 2,2',6,6'-TETRAISOPROPYL-4,4'-BIPHENOL LIPID MICROSPHERE PREPARATIONS AND PREPARATION METHODS THEREFOR - This invention relates to a 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparation having 2,2′,6,6′-tetraisopropyl-4,4′-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water. | 2014-12-18 |
20140370102 | METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. | 2014-12-18 |
20140370103 | NON-IMMUNOGENIC DELIVERY VEHICLE FOR BETTA-, GAMMA-, AND DELTA-TOCOPHEROLS AND METHODS OF USING AND MAKING SAME - This disclosure provides microparticles for the delivery of non-immunogenic compositions providing delivery of β-, γ- and/or δ-tocopherols. | 2014-12-18 |
20140370104 | PHARMACEUTICAL FORMULATION AND METHOD FOR TREATING ACID CAUSED GASTROINTESTINAL DISORDERS - Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at least one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump inhibitor and at least one antacid. | 2014-12-18 |
20140370105 | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH 6-MERCAPTOPURINE - Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects. | 2014-12-18 |
20140370106 | BEADLETS COMPRISING HOP ACID SALTS IN A PROTEIN MATRIX - The present invention relates a process of production of beadlets comprising at least one hop acid salt in a matrix comprising at least one protein, to such beadlets and to the use of such specific beadlets in feed as well as in feed premixes. | 2014-12-18 |
20140370107 | MULTILAYER MICROINCAPUSLATED PROBIOTIC BACTERIA - A multilayer microencapsulated lactic bacteria and bifidobacteria, preferably bacteria with probiotic activity, and the use thereof to prepare a food product, supplement product, medical device or pharmaceutical composition or water- and/or fruit-based beverage are described. A process for preparing multilayer microencapsulated lactic bacteria and bifidobacteria, preferably bacteria with probiotic activity is described. A food product is described selected from water, water- and/or fruit-based beverages, milk, fresh whole milk, partially skimmed milk, powdered milk, cheese, fresh cheese, aged cheese, grated cheese, butter, margarine, yogurt, cream, milk- and chocolate-based custards, custards for sweets, jams and oily suspensions having bacteria, preferably multilayer microencapsulated lactic bacteria and bifidobacteria with probiotic activity. | 2014-12-18 |
20140370108 | Pharmacokinetics of S-Adenosylmethionine Formulations - Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning. | 2014-12-18 |
20140370109 | Stabilized Granules Containing Glyceryl Trinitrate - Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer. | 2014-12-18 |
20140370110 | POLYMER CONJUGATED PROTEIN MICELLES - The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also encompasses a prolamine protein conjugated to a polymer, such as a polyethylene glycol (PEG) chain, which conjugates can be used to prepare micelle assemblies. The invention further encompasses methods of encapsulating molecules using the conjugates of the invention. The micelle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an encapsulated agent in vivo, protecting an encapsulated agent against degradation, and enhancing the water solubility of a drug or other agent. | 2014-12-18 |
20140370111 | PROTEIN DELIVERY FROM STEM CELL MICROCARRIERS - Disclosed are methods and compositions of microbead carriers for delivery of cells and other biologically active substances to diseased or damaged tissue in a subject in need thereof. | 2014-12-18 |
20140370112 | Multiparticulate L-Carnitine Compositions and Related Methods - An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body. | 2014-12-18 |
20140370113 | HYDROCORTISONE CONTROLLED RELEASE FORMULATION - The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression. | 2014-12-18 |
20140370114 | HOMOPOLYMER NANOPARTICLES BY SELF-EMULSION POLYMERIZATION REACTION AND PREPARATION METHOD THEREOF - Disclosed herein is a preparation method of homopolymer nanoparticles without using a surfactant. The homopolymer nanoparticles prepared thereby are expected to be widely used not only as a template of a semiconductor metal oxide, a drug delivery system (DDS), an electron transport layer (ETL), and a seed having vertical structural shape, but also in a high precision field such as replacement of an organic device polystyrene bead film. | 2014-12-18 |
20140370115 | LIPID EXTRACTION PROCESSES - The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods. | 2014-12-18 |
20140370116 | Method and System for Treatment of Biological Tissue - A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component and a bioactive agent component. In a preferred embodiment, the ECM scaffold component comprises mesothelial tissue and the bioactive agent comprises a statin. | 2014-12-18 |
20140370117 | Low-Concentration Nutritional Composition - The present invention provides an enteral nutritional composition with which the labor of administering water between meals can be saved. The enteral nutritional composition comprises proteins, carbohydrates and lipids, with the calories per ml of the composition being less than 1 kcal and the moisture content being 30 percent by mass or more. | 2014-12-18 |
20140370118 | METHODS OF TREATING MALNUTRITION - Methods of treating malnutrition are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea. | 2014-12-18 |
20140370119 | Arsenic Compound Solution and Albumin Nanoparticle and Lyophilized Preparation Entrapping Arsenic Compound Prepared Using Same - An arsenic compound solution, and an albumin nanoparticle and a lyophilized preparation prepared using same and entrapping an arsenic compound. The arsenic compound solution is prepared using the following method: adding As | 2014-12-18 |
20140370120 | Methods of Nourishing Animals - The present invention relates to methods of maintaining, and methods of restoring, a desired calcium homeostasis in a non-human terrestrial animal by administering an effective amount of one or more Calcium-Sensing Receptor modulators (CaSRs) to the animal. The invention further provides methods of reducing foot lesions in chickens. The invention also relates to food compositions useful in the methods of the invention. | 2014-12-18 |
20140370121 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF - Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment. | 2014-12-18 |
20140370122 | METHODS AND COMPOSITIONS FOR PROMOTING ACTIVITY OF ANTI-CANCER THERAPIES - The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin. | 2014-12-18 |
20140370123 | SKIN EXTERNAL COMPOSITION COMPRISING A SEA SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND THE USE THEREOF - A skin external composition comprising a combination of salt and sugar as an active ingredient in an amount effective to treat and prevent vaginosis, together with a pharmaceutically acceptable carrier, and the use thereof. | 2014-12-18 |
20140370124 | MULTI-PURPOSE ANTI-ITCH TREATMENT - There is disclosed a formulation of a transdermal skin treatment effective in inhibition of itch sensation. In an embodiment, the formulation includes a solvent mixture of alcohols, glycols and water combined to provide a solubility parameter between 20 Pa | 2014-12-18 |
20140370125 | METHOD FOR PRODUCING NO/N2 GASEOUS MIXTURES INTENDED FOR THE MEDICAL FIELD - The invention relates to a method for producing an NO/N | 2014-12-18 |
20140370126 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR ASTHMA, CONTAINING LAGERSTROEMIA OVALIFOLIA EXTRACT OR FRACTION THEREOF AS ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases or asthma comprising a | 2014-12-18 |
20140370127 | ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF TETRACERA SCANDENS AND USE THEREOF - A composition for preventing or treating a viral infection, which includes an ethanol extract of | 2014-12-18 |
20140370128 | COMPOSITION FOR TREATING ATOPIC DERMATITIS COMPRISING EXTRACTS OF BAMBOO AND SCUTELLARIA - The present invention relates to a composition comprised of a plant extract as an active component, specifically, Bamboo extract and | 2014-12-18 |
20140370129 | DOSING REGIMEN AND METHOD FOR TREATING CANCER USING A COIX SEED OIL EMULSION - A method for administering a Kanglaite Injection (KLTi) composition comprising | 2014-12-18 |
20140370130 | PRODUCTS CONTAINING HIGHLY UNSATURATED FATTY ACIDS FOR USE BY WOMEN AND THEIR CHILDREN DURING STAGES OF PRECONCEPTION, PREGNANCY AND LACTATION/POST-PARTSUM - A method and product for improving maternal and child health through nutrition. Omega-6 fatty acid and/or omega-3 fatty acid are provided to a woman and/or child prior to, during and/or after pregnancy to improve the health of the woman and her child. The ratios of the omega-6 and omega-3 fatty acids vary during various stages, e.g., pre-pregnancy, pregnancy and post-pregnancy. The omega-6 and omega-3 fatty acids can be in a variety of forms, such as at least one of highly purified algal oil comprising 70% by weight or more of the desired HUFA, triglyceride oil combined with phospholipid, phospholipid, protein and phospholipid combination, or dried marine microalgae. | 2014-12-18 |
20140370131 | Pharmaceutical Composition for Protecting Brain Neurons Comprising Plumula Nelumbinis Extract as Active Ingredient - The present invention relates to a pharmaceutical composition and food composition comprising Nelumbo nucifera seed extract as an active ingredient for the protection of brain nerve cells. Particularly, the composition is characterized by having an activity of removing reactive oxygen species (ROS) or an antioxidant activity. More particularly, the antioxidant activity is characterized by the activity of removing 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals or the activity of removing hydrogen peroxide (H2O2). Also, the present invention is extracted from a natural substance and is thus safe for the human body and provides fundamental data to the food and pharmaceutical fields, which use products derived from natural substances. | 2014-12-18 |
20140370132 | COMPOSITION CONTAIING JETBEAD EXTRACTS - The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, which comprises, as an active ingredient, a | 2014-12-18 |
20140370133 | COSMETIC PRODUCTS FOR AGED SKIN - A cosmetic product having a pH value of 3.0 to 5.2 is disclosed that is specifically suitable for treating aged skin and irritations occurring there. The cosmetic product is preferably a barrier-stabilizing lotion or a barrier-stabilizing cream that contains a dry extract obtained from lady's mantle ( | 2014-12-18 |
20140370134 | Composition comprising Rhizoma Coptidis, Cortex Phellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases - This invention is in the field of pharmaceuticals, health supplements and chemical industries. In particular, this invention relates a herbal composition that compensates the Aβ increasing effects of existing treatment, and on the regulatory processing of amyloid-β protein precursor (APP), therefore presenting a significantly more potent treatment for neurodegenerative diseases that does not associate with any β-amyloid increasing effect. | 2014-12-18 |
20140370135 | USE OF EXTRACTS OF CAPRARIA BIFLORA IN THE PREVENTION AND/OR TREATMENT OF SENILE CATARACTS - The invention provides methods for treating and/or preventing the recurrence of a senile cataract, and/or for inhibiting the development of a senile cataract and/or an incipient senile cataract, in a human or animal subject. The invention further provides nutraceutical compositions suited for the same, derived from an extract of the plant | 2014-12-18 |
20140370136 | FERMENTED POMEGRANATE OIL COMPOSITION AND METHOD OF PREPARING THE SAME - Disclosed are a fermented pomegranate oil composition wherein pomegranates are immersed in edible vegetable oil so that the pomegranates are fermented under anaerobic conditions and active ingredients of the pomegranates are efficiently released to the edible oil to obtain edible vegetable oil containing active ingredients of pomegranates which is useful for cosmetics, functional foods and medicine materials, and a method of preparing the same. | 2014-12-18 |
20140370137 | Tire Vulcanization Mold and Manufacturing Method Therefor - A manufacturing method for manufacturing a tire vulcanization mold may include: providing a projection that projects in the thickness direction midway in the vertical direction of the blade; providing a communicating portion that extends from below the projection to above the projection and that penetrates the blade in the thickness direction; forming the exhaust groove on the tire molding surface so the initial thickness of the exhaust groove is thinner than the thickness of the projection; inserting and positioning the bottom end of the blade in the exhaust groove; forming a small gap between an upper side portion of the projection of the embedded blade and the exhaust groove by embedding the positioned blade by press fitting in the depth direction into the exhaust groove while expanding the exhaust groove in the thickness direction by the projection; and linking the small gap and the exhaust hole through the communicating portion. | 2014-12-18 |
20140370138 | METHOD OF REDUCING FRICTION - A method of reducing the friction between the wall(s) of a mold and the outer wall(s) of a metal container fitting snugly in the mold and containing a metal ammine complex salt which is uniaxially compacted within the container, comprises a) treating or covering the inner wall(s) of the container with a lubricant before the metal ammine salt is filled into the container, or b) mixing a solid lubricant with the metal ammine salt to be filled into the container is, or c) treating or covering a gas-permeable enclosure made of a flexible material and wrapped around the solid metal ammine salt with a lubricant before the solid metal ammine salt wrapped into the envelope is filled into the container, or a combination of a) and b) or a) and c). A lubricated container and a lubricated enclosure each containing a metal ammine salt is also disclosed. | 2014-12-18 |
20140370139 | TEMPERATURE MONITORING DEVICE FOR INJECTION MOLDING MACHINE - A temperature monitoring device for an injection unit of an injection molding machine is provided with a heater to heat a nozzle and a heating cylinder, a temperature sensor to detect a current temperature of the nozzle and the heating cylinder or around the heating cylinder, and an electromagnetic locking device to prohibit a safety door from opening when the current temperature detected by the temperature sensor exceeds a predetermined opening operation prohibited temperature. | 2014-12-18 |